Table 1.
Baseline Characteristics of Study Sample
| Variable | Total (N=1110) | Nonobstructive (N=513) | Obstructive (N=597) | P Value | |
|---|---|---|---|---|---|
| No SRT in Follow‐Up (N=402) | SRT in Follow‐Up (N=195) | ||||
| Age, y | 80±5 | 80±5 | 80±5 | 79±5 | 0.11 |
| Female sex, n (%) | 727 (66) | 333 (65) | 265 (66) | 129 (66) | 0.39 |
| Hypertension, n (%) | 795 (72) | 357 (70) | 288 (72) | 140 (72) | 0.18 |
| Hyperlipidemia, n (%) | 759 (68) | 619 (68) | 140 (72) | 140 (72) | 0.15 |
| Diabetes mellitus, n (%) | 189 (17) | 97 (19) | 61 (15) | 31 (16) | 0.33 |
| Chronic kidney disease, n (%) | 129 (12) | 73 (14%) | 42 (10%) | 14 (7%) | 0.02 |
| COPD | 141 (13) | 73 (14) | 48 (12) | 20 (10) | 0.31 |
| History of stroke, n (%) | 113 (10) | 94 (10) | 19 (10) | 19 (10) | |
| Documented CAD, n (%) | 119 (11) | 41 (8) | 40 (10) | 38 (20) | 0.01 |
| Genetic testing for HCM,* n (%) | 38 (3) | 17 (3) | 13 (3) | 8 (4) | 0.27 |
| Family history of HCM, n (%) | 19 (2) | 5 (1) | 5 (1) | 9 (5) | 0.003 |
| Family history of SCD, n (%) | 52 (5) | 14 (3) | 21 (5) | 17 (9) | 0.003 |
| History of SCD, n (%) | 9 (0.8) | 4 (0.7) | 3 (0.1) | 2 (0.1) | 0.83 |
| History of NSVT, n (%) | 78 (7) | 31 (6) | 2270 (7) | 20 (10) | 0.14 |
| History of syncope, n (%) | 133 (12) | 75 (15) | 12 (3), none exertional | 46 (24) | 0.009 |
| History of AF, n (%) | 325 (31) | 174 (34) | 90 (22) | 61 (31) | <0.001 |
| AF on baseline ECG, n (%) | 102 (10) | 66 (13) | 25 (6) | 11 (6) | 0.03 |
| History of prior alcohol septal ablation, n (%) | 43 (4) | 16 (3) | 0 | 27 (14) | <0.001 |
| History of prior surgical myectomy, n (%) | 35 (3%) | 19 (4%) | 9 (2%) | 7 (4%) | 0.42 |
| Implantable defibrillator, n (%) | 34 (3) | 20 (4) | 10 (3) | 4 (2) | 0.31 |
| Permanent pacemaker, n (%) | 75 (7) | 20 (4) | 20 (5) | 35 (18) | <0.001 |
| Aspirin, n (%) | 724 (65) | 554 (61) | 170 (87) | 170 (87) | <0.001 |
| Beta‐blockers, n (%) | 899 (81) | 389 (76) | 335 (83%) | 175 (90) | <0.01 |
| Calcium channel blocker, n (%) | 221 (20) | 84 (16) | 74 (18) | 64 (33) | <0.001 |
| Disopyramide, n (%) | 31 (3) | 9 (2) | 3 (6) | 11 (6) | 0.01 |
| Anticoagulation, n (%) | 272 (25) | 141 (27) | 60 (15) | 71 (36) | <0.001 |
| Angina, n (%) | 431 (19) | 114 (12) | 317 (24) | 317 (24) | <0.001 |
| NYHA class, n (%) | |||||
| I | 130 (12) | 66 (13) | 64 (16) | 0 | |
| II | 763 (69) | 405 (79) | 338 (84) | 20 (10) | <0.001 |
| III | 192 (17) | 37 (7) | 0 | 155 (80) | |
| IV | 25 (2) | 5 (1) | 0 | 0 (10) | |
| Society of Thoracic Surgeons score | 8.6±6 | 8.6±7 | 8.1±15 | 9.2±17 | 0.144 |
| ACC/AHA SCD risk factors, n (%) | |||||
| 0 | 896 (80) | 426 (83) | 330 (82) | 140 (72) | |
| 1 | 195 (18) | 80 (16) | 67 (17) | 48 (25) | 0.01 |
| ≥2 | 19 (2) | 7 (1) | 5 (1) | 7 (3) | |
| ESC % 5‐y SCD risk score | 1.54±1.2 | 1.11±0.7 | 1.6±1 | 2.4±2 | <0.001 |
| ESC % 5‐y SCD risk categories, n (%) | |||||
| Low risk (<4%) | 1052 (95) | 506 (99) | 381 (95) | 1654 (85) | |
| Intermediate risk (4%–6%) | 44 (4) | 7 (1) | 15 (4) | 22 (11) | <0.001 |
| High risk (>6%) | 14 (1%) | 0 | 6 (2%) | 8 (4%) | |
ACC/AHA indicates American College of Cardiology/American Heart Association; AF, atrial fibrillation; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ESC, European Society of Cardiology; HCM, hypertrophic cardiomyopathy; LVOT, left ventricular outflow tract; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death; and SRT, septal reduction therapy.
*
No patients were genotype positive for HCM.